Actively Recruiting
Heart Failure and Aortic Stenosis Transcriptome
Led by IRCCS Policlinico S. Donato · Updated on 2025-04-30
500
Participants Needed
2
Research Sites
604 weeks
Total Duration
On this page
Sponsors
I
IRCCS Policlinico S. Donato
Lead Sponsor
O
Ospedale San Raffaele
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers. To this purpose, both tissue and blood specimens will be collected and patients will be compared to individuals not affected by cardiovascular diseases.
CONDITIONS
Official Title
Heart Failure and Aortic Stenosis Transcriptome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 40 and 75 years
- Non end-stage heart failure with left ventricle restoration surgery, End Systolic Volume Index (ESVI) >35 ml/m2, Ejection Fraction (EF) <40%, and previous transmural anterior myocardial infarction
- End-stage heart failure with left ventricle assist device surgery, age 40-75, Ejection Fraction (EF) <25%, and End Systolic Volume Index (ESVI) 60 ml/m2
- Aortic stenosis patients undergoing aortic valve replacement with intracardial pressure difference >40 mmHg and septal diameter 1.3 cm
You will not qualify if you...
- Non end-stage heart failure with End Systolic Volume Index (ESVI) <35 ml/m2, Ejection Fraction (EF) >40%, unknown time since myocardial infarction, pregnancy, other genetic diseases, neoplasms, collagenopathies, chemo/radiotherapy, prolonged corticosteroid use, infections, or positive for HIV, Hepatitis B (not vaccination), or Hepatitis C
- End-stage heart failure with Ejection Fraction (EF) >25%, unknown time since myocardial infarction, pregnancy, other genetic diseases, neoplasms, collagenopathies, chemo/radiotherapy, prolonged corticosteroid use, infections, or positive for HIV, Hepatitis B (not vaccination), or Hepatitis C
- Aortic stenosis with coronaropathies, pregnancy, other genetic diseases, neoplasms, collagenopathies, chemo/radiotherapy, prolonged corticosteroid use, infections, or positive for HIV, Hepatitis B (not vaccination), or Hepatitis C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Irccs Policlinico San Donato
San Donato Milanese, Milan, Italy, 20097
Actively Recruiting
2
Ospedale San Raffaele
Milan, Italy, 20132
Actively Recruiting
Research Team
F
Fabio Martelli, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here